Clearpoint Neuro, Inc. (CLPT) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Xtant Medical Holdings, Inc.

Bioventus, Inc.

TELA Bio, Inc.

Inogen, Inc.

Harvard Bioscience, Inc.

Sight Sciences, Inc.

Stereotaxis, Inc.

Clearpoint Neuro, Inc.

Semler Scientific, Inc.

Celcuity, Inc.

Jin Medical International Ltd.

Why is Clearpoint Neuro, Inc. ?

Flat results in Sep 25

INTEREST(9M) At USD 0.62 MM has Grown at inf%
NET PROFIT(HY) At USD -11.73 MM has Grown at -25.01%
ROCE(HY) Lowest at -103.13%

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -31.95%, its profits have fallen by -27.5%

Below par performance in long term as well as near term

Along with generating -31.95% returns in the last 1 year, the stock has also underperformed S&P 500 in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Clearpoint Neuro, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Clearpoint Neuro, Inc.

-31.95%

0.57

100.53%

S&P 500

14.9%

0.77

19.29%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

22.75%

EBIT Growth (5y)

-217.41%

EBIT to Interest (avg)

-16.61

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.59

Sales to Capital Employed (avg)

0.85

Tax Ratio

0.09%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

40.56%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

20.67

EV to EBIT

-14.06

EV to EBITDA

-15.31

EV to Capital Employed

44.35

EV to Sales

9.30

PEG Ratio

Dividend Yield

ROCE (Latest)

-315.47%

ROE (Latest)

-145.77%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

7What is working for the Company

NET PROFIT(HY)

Higher at USD -11.73 MM

INVENTORY TURNOVER RATIO(HY)

Highest at 1.95 times

RAW MATERIAL COST(Y)

Fallen by -6% (YoY

OPERATING PROFIT MARGIN(Q)

Highest at -54.73 %

-11What is not working for the Company

INTEREST(9M)

At USD 0.62 MM has Grown at inf%

NET PROFIT(HY)

At USD -11.73 MM has Grown at -25.01%

ROCE(HY)

Lowest at -103.13%

DEBT-EQUITY RATIO (HY)

Highest at -15.6 %

Here's what is working for Clearpoint Neuro, Inc.

Net Profit

Higher at USD -11.73 MM

than preceding 12 month period ended Sep 2025

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

Inventory Turnover Ratio

Highest at 1.95 times and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Operating Profit Margin

Highest at -54.73 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Raw Material Cost

Fallen by -6% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Clearpoint Neuro, Inc.

Interest

At USD 0.62 MM has Grown at inf%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Net Profit

At USD -11.73 MM has Grown at -25.01%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)

Debt-Equity Ratio

Highest at -15.6 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio